Choosing Second-Line Therapy for HER2+ Gastric Cancer
Bassel El-Rayes, MD, discusses how he approaches second-line therapy for patients with HER2-positive gastric cancer.
Trastuzumab Deruxtecan for HER2+ Gastric Cancer
Bassel El-Rayes, MD, an expert in oncology, discusses the DESTINY-Gastric01 trial of trastuzumab deruxtecan in HER2+ gastric cancer and comments on implications for second-line treatment and beyond.
Future Directions and Unmet Needs for Gastric Carcinoma
The DESTINY-Gastric01 Trial and Mechanisms of Resistance in Gastric Carcinoma
Treatment Options for Gastric Carcinoma
Molecular Testing for Gastric Carcinoma
Patient Case With HER2+ Gastric Carcinoma
A 66-Year-Old Man With Gastric Carcinoma
Bassel El-Rayes, MD, reviews the case of a 66-year old man with gastric carcinoma and discusses the disease from diagnosis to unmet needs.
Analyzing Necessary Steps for Treating Patients with mCRC
Bassel El-Rayes, MD, discusses the key points physicians should consider when treating a patient with metastatic colorectal cancer.
